Lung Cancer News
Pyrotinib showed activity in HER2-positive non-small cell lung cancer, both in preclinical experiments and in patients enrolled in a phase 2 trial.
Use of durvalumab consolidation therapy in all eligible patients with NSCLC was deemed cost-effective, despite its incremental budgetary consequence of $768 million in year 1.
The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.
Researchers found that recurrences were rare for patients receiving adjuvant erlotinib.
Researchers reported that ablation of pulmonary malignant tumors may be a safe treatment option in select patients.
Combination therapy showed activity in epidermal growth factor receptor-mutated, mesenchymal-epithelial transition factor-dysregulated non-small-cell lung cancer.
This trial in NSCLC was terminated early when the investigational drug become unavailable following the dissolution of a partnership between the drug's codevelopers.
Analyzing ctDNA following drug treatment could help identify nonresponders to immunotherapy.
Scientific models project a continued decrease in lung cancer mortality.
Management strategies were identified for lung cancer patients who experienced hyperprogressive disease during treatment with nivolumab.
Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
The 2 most common resistance mechanisms were MET amplification, EGFR C797S mutation.
Brigatinib significantly delayed time to intracranial progression and prolonged PFS compared with crizotinib in patients with ALK+ NSCLC with intracranial metastases.
Approximately one-third of patients with NSCLC with a therapeutically targetable mutation detected in plasma were able to avoid invasive biopsy.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
Only One-Third of Trials Supporting FDA Approval of Cancer Drugs Met the ESMO-MCBS Criteria for Substantial Clinical Benefit
The only single-arm cancer trials to show a substantial benefit were those for osimertinib for T790-mutated NSCLC and crizotinib for ALK-rearranged NSCLC.
Many immunotherapy-based combinations are being studied in NSCLC, with TMB emerging as a potential predictive biomarker.
Tislelizumab, an anti-PD-1 antibody, demonstrated antitumor activity in phase 1 and phase 2 trials of Chinese patients with advanced lung cancers.
CT lung cancer screening substantially reduces lung cancer deaths among asymptomatic patients at high risk for developing lung cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Evidence Grows Linking BIA-ALCL to Textured Surface of Some Breast Implants
- Could Cytostatic Drugs Unleash Antitumor Immunity in Lung Cancer?
- Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL
- Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
- Fermented Dairy and Cancer
- In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression
- Fermented Dairy and Cancer
- Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot
- Spending on Medical DTC Advertising Increased Dramatically Over the Past 20 Years
- SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC